Recro Pharma (REPH): Second Meloxicam Phase 3 Trial Achieves Positive Results - REPH

November 29, 2016 7:15 AM EST Send to a Friend
H.C. Wainwright analyst, Ed Arce, reiterated his Buy rating on shares of Recro Pharma (NASDAQ: REPH) after the company announced ...

To continue reading this article and more like it please sign-in or join today (FREE!)

Member Login